by [email protected] | May 4, 2019 | Endocrine, Publication
Abstract Authors: Wei W, Pan C, Xie L, Baser O. Objective: To evaluate real-world treatment persistence among patients with type 2 diabetes mellitus (T2DM) initiating treatment with insulin. Methods: Patient-level data were pooled from 3 previously published...
by [email protected] | May 3, 2019 | Endocrine, Publication
Abstract Authors: Baser O, Tangirala K, Wei W, Xie L. Background: In patients with type 2 diabetes mellitus, basal-bolus strategies can improve treatment by offering dosing flexibility, and improved satisfaction, adherence, and clinical outcomes. The purpose of...
by [email protected] | May 2, 2019 | Endocrine, Publication
Abstract Authors: Miao R, Wei W, Baser O, Xie L. Introduction: Patients with type 2 diabetes mellitus (T2DM) often require intensification of basal insulin therapy. This retrospective, observational study compared real-world outcomes in US patients with T2DM...
by [email protected] | May 1, 2019 | Endocrine, Publication
Abstract Authors: Xie L, Wei W, Pan C, Baser O. Objective: To evaluate the real-world rates of hypoglycemia and related costs among patients with type 2 diabetes mellitus (T2DM) who initiated insulin glargine with either a disposable pen or vial-and-syringe....
by [email protected] | Apr 30, 2019 | Endocrine, Publication
Abstract Authors: Wang L, Wei W, Miao R, Xie L, Baser O. Objectives: To compare real-world outcomes of initiating insulin glargine (GLA) vs neutral protamine Hagedorn (NPH) insulin among employees with type 2 diabetes mellitus (T2DM) who had both employer-sponsored...
by [email protected] | Apr 29, 2019 | Endocrine, Publication
Abstract Authors: Xie L, Zhou S, Wei W, Gill J, Pan C, Baser O. Objective: The study was designed to evaluate real-world data on clinical and economic outcome differences between patients with type 2 diabetes mellitus (T2DM) who use insulin glargine with...
